Creative Planning
DMAC icon

Creative Planning’s DiaMedica Therapeutics DMAC Stock Holding History

Creative Planning’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$227K Sell
33,599
-25,256
-43% -$200K ﹤0.01% 3645
2025
Q4 		$468K Buy
58,855
+20,065
+52% +$150K ﹤0.01% 2904
2025
Q3 		$266K Buy
+38,790
New +$210K ﹤0.01% 3240

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Creative Planning's DMAC Position: Q1 2026 in Review

Creative Planning reduced its DiaMedica Therapeutics (DMAC) stake by 43% in Q1 2026, selling an estimated $200K and leaving 33,599 shares worth $227K. The position accounts for ﹤0.01% of the portfolio, ranked #3645.

Creative Planning first reported a position in DMAC in Q3 2025 and has held it in 3 quarters since. The position peaked at $468K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Creative Planning held 33,599 shares of DiaMedica Therapeutics worth $227K as of Q1 2026.
  • Creative Planning sold 25,256 DiaMedica Therapeutics shares in Q1 2026, an estimated $200K.
  • DiaMedica Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #3645 holding.
  • Creative Planning first reported a position in DiaMedica Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Creative Planning's DiaMedica Therapeutics position peaked at $468K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.